IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells

Blood

Volumn 114, Issue 2, 2009, Pages 360-370

  Shi, Ping ^a   Lai, Raymond ^b   Lin, Quan ^a   Iqbal, Abid S ^a   Young, Leah C ^c   Kwak, Larry W ^a   Ford, Richard J ^a   Amin, Hesham M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; NUCLEOPHOSMIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; P80(NPM ALK) PROTEIN; P80(NPM-ALK) PROTEIN; PROTEIN TYROSINE KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; T LYMPHOCYTE; ANIMAL; CELL LINE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROTEIN BINDING; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MICE; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 67651115787     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-125658     Document Type: Article

References (64)

1. Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986;5:2503-2512.
2. De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov. 2002;1:769-783. (Pubitemid 37361561)
3. Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB, Wang LH. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem. 2000;275:15099-15105. (Pubitemid 30337231)
4. Gual P, Baron V, Lequoy V, Van Obberghen E. Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor. Endocrinology. 1998; 139:884-893. (Pubitemid 28510102)
5. Nakae J, Barr V, Accili D. Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR. EMBO J. 2000;19:989-996. (Pubitemid 30119824)
6. Galetic I, Andjelkovic M, Meier R, Brodbeck D, Park J, Hemmings BA. Mechanism of protein kinase B activation by insulin/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase-significance for diabetes and cancer. Pharmacol Ther. 1999;82:409-425. (Pubitemid 29255934)
7. Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, Larsson O. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene. 2004; 23:7854-7862. (Pubitemid 39457035)
8. Criswell T, Beman M, Araki S, et al. Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Erg-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem. 2005; 280:14212-14221. (Pubitemid 40517323)
9. Baserga R, Sell C, Porcu P, Rubini M. The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif. 1994;27:63-71. (Pubitemid 24053398)
10. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A. 1993;90:11217-11221. (Pubitemid 23354400)
11. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20-47. (Pubitemid 46220849)
12. van Golen CM, Schwab TS, Kim B, et al. Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone. Cancer Res. 2006;66:6570-6578. (Pubitemid 44085612)
13. Tang Y, Zhang D, Fallavollita L, Brodt P. Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res. 2003;63:1166-1171. (Pubitemid 36348689)
14. Guvakova MA, Adams JC, Boettiger D. Functional role of α-actinin, PI 3-kinase and MEK1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells. J Cell Sci. 2002;115:4149-4165.
15. Mauro L, Bartucci M, Morelli C, Ando S, Surmacz E. IGF-I receptor-induced cell-cell adhesion of MCF-7 breast cancer cells requires the expression of junction protein ZO-1. J Biol Chem. 2001; 276:39892-39897. (Pubitemid 37391401)
16. Chernicky CL, Yi L, Tan H, Gan SU, Ilan J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther. 2000;7:384-395. (Pubitemid 30210405)
17. Lopez T, Hanahan D. Elevated levels of the IGF-I receptor convey invasion and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2002;1:339-353. (Pubitemid 41039136)
18. Adachi Y, Lee CT, Coffee K, et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology. 2002;123:1191-1204.
19. Dunn SE, Ehrlich M, Sharp NJ, et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 1998;58: 3353-3361. (Pubitemid 28371076)
20. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 2002;62:2942-2950. (Pubitemid 34525783)
21. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 2003;63:5073-5083.
22. Lee CT, Park KH, Adachi Y, et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther. 2003;10:57-63. (Pubitemid 36222077)
23. Burfeind P, Chernicky CL, Rininsland F, Ilan J, Ilan J. Antisense RNAto the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci U S A. 1996;93:7263-7268. (Pubitemid 26243537)
24. Singleton JR, Randolph AE, Feldman EL. Insulinlike growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res. 1996;56:4522-4529. (Pubitemid 26330465)
25. Hofmann F, Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today. 2005;10: 1041-1047. (Pubitemid 41074142)
26. Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene. 2003;22:6589-6597. (Pubitemid 37372339)
27. Baserga R. Controlling IGF-receptor function: a possible strategy for tumor therapy. Trends Biotechnol. 1996;14:150-152. (Pubitemid 26162077)
28. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumors. Clin Cancer Res. 2007;13:5834-5840. (Pubitemid 47583908)
29. McCubrey JA, Steelman LS, MayoMW, Algate PA, Dellow RA, Kaleko M. Growth-promoting effects of insulin-like growth factor-1 (IGF-1) on hematopoietic cells: overexpression of introduced IGF-1 receptor abrogates interleukin-3 dependency of murine factor-dependent cells by a ligand-dependent mechanism. Blood. 1991;78:921-929.
30. Reiss K, Porcu P, Sell C, Pietrzkowski Z, Baserga R. The insulin-like growth factor 1 receptor is required for the proliferation of hemopoietic cells. Oncogene. 1992;7:2243-2248.
31. Bertrand FE, Steelman LS, Chappell WH, et al. Synergy between an IGF-1R antibody and Raf/MEK/ ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia. 2006;20:1254-1260.
32. Walsh PT, Smith LM, O'Connor R. Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes. Immunology. 2002;107:461-471. (Pubitemid 36693651)
33. Menu E, Jernberg-Wiklund H, Stromberg T, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood. 2006;107:655-660. (Pubitemid 43076391)
34. Stromberg T, Ekman S, Girnita L, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood. 2006;107:669-678. (Pubitemid 43076393)
35. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5:221-230.
36. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997;14:439-449. (Pubitemid 27087107)
37. Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 1997;14:2175-2188. (Pubitemid 27248229)
38. Delsol G, Falini B, Muller-Hermelink HK, et al. Anaplastic large cell lymphoma (ALCL), ALKpositive. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2008:312-316.
39. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263:1281-1284.
40. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene. 1994;9:1567-1574. (Pubitemid 24163381)
41. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995;86:1954-1960. (Pubitemid 27313594)
42. + lymphoma: clinico-pathological findings and outcome. Blood. 1999;93:2697-2706.
43. + anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92:3591-3598.
44. Brugieres L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology. Ann Oncol. 2000;11:53-58. (Pubitemid 30084579)
45. Laver JH, Kraveka JM, Hutchinson RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of theAPO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23:541-547.
46. Fujimoto J, Shiota M, Iwahara T, et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A. 1996;93:4181-4186. (Pubitemid 26146730)
47. + anaplastic large-cell lymphoma. Blood. 2007;110:2259-2267.
48. Liu J-P, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulinlike growth factor (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993;75:59-72. (Pubitemid 23306021)
49. Pietrzkowski Z, Lammers R, Carpenter G, et al. Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ. 1992;3:199-205.
50. Rosengren L, Vasilcanu D, Vasilcanu R, et al. IGF-1R tyrosine kinase expression and dependence in clones of IGF-1R knockout cells (R-). Biochem Biophys Res Commun. 2006;347:1059-1066. (Pubitemid 44137345)
51. + anaplastic large-cell lymphoma cells. Blood. 2006;108:2407-2415.
52. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 2004;64:236-242. (Pubitemid 38114104)
53. Bai R-Y, Dieter P, Peschel C, Morris SW, Duyster J. Nucelophosmin- anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity. Mol Cell Biol. 1998;12:6951-6961. (Pubitemid 28533016)
54. Chikamori M, Fujimoto J, Tokai-Nishizumi N, Yamamoto T. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation. Oncogene. 2007;26:2950-2954. (Pubitemid 46701442)
55. Tartari CJ, Gunby RH, Coluccia AML, et al. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem. 2008;283:3743-3750.
56. Amin HM, Medeiros LJ, Ma Y, et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene. 2003;22:5399-5407. (Pubitemid 37072194)
57. c-src to mediate its mitogenicity. Blood. 2004;103:1464-1471.
58. Meyn MA, Wilson MB, Abdi FA, et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem. 2006;281:30907-30916.
59. Amin HM, McDonnell TJ, Ma Y, et al. Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene. 2004;23:5426-5434. (Pubitemid 39044053)
60. Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood. 2005;105:827-829.
61. Gu T-L, Tothova Z, Scheijen B, Griffin JD, Gilliland DG, Sternberg DW. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood. 2004;103:4622-4629. (Pubitemid 38745994)
62. Lakshmikuttyamma A, Pastural E, Takahashi N, et al. Bcr-Abl induces autocrine IGF-1 signaling. Oncogene. 2008;27:3831-3844. (Pubitemid 351862064)
63. Shi P, Chandra J, Sun X, et al. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukemia cells J Cell Mol Med. Prepublished online June 5, 2009, as DOI 10.1111/j.1582-4934.2009.00795.X.
64. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene. 2000;19: 5574-5581.